Dimethyl-[2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethyl]azanium;chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Dimethyl-[2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethyl]azanium;chloride
• 英文别名: dimethyl-[2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethyl]azanium;chloride
• 化学式: C18H20ClN3O2
• 分子量: 345.8
• InChiKey: CMBNCCBWKKFFHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.77
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  51.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  二甲氨基氯乙烷盐酸 、 2-(3-phenyl-1,2,4-oxadiazol-5-yl) phenol 在 二甲氨基氯乙烷盐酸 作用下， 以64的产率得到Dimethyl-[2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethyl]azanium;chloride
  参考文献：
  名称：

  Oxadiazoles, processes for their preparation and their use as medicaments

  摘要：

  本发明涉及一般式(I)的噁二唑衍生物，其中X、Y、Z和R1如规范和要求所述，以及制备它们的过程和它们作为制药组合物的用途。

  公开号：

  US06277872B1

文献信息

• NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER
  申请人：Ikonomidou, Hrissanthi

  公开号：EP1124553A1

  公开（公告）日：2001-08-22
• THERAPEUTIC COMBINATIONS, LIQUID PHARMACEUTICAL COMPOSITIONS, KITS FOR THEIR PREPARATION, AND METHODS OF THEIR USE
  申请人：Prevep LLC

  公开号：EP3955905A1

  公开（公告）日：2022-02-23
• US6797692B1
  申请人：——

  公开号：US6797692B1

  公开（公告）日：2004-09-28
• [EN] NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER<br/>[FR] NOUVELLE UTILISATION D'ANTAGONISTES DU GLUTAMATE POUR LE TRAITEMENT DU CANCER
  申请人：IKONOMIDOU HRISSANTHI

  公开号：WO2000024395A1

  公开（公告）日：2000-05-04

  New use of glutamate antagonists (NMDA, AMPA and kainate receptor antagonists) and their physiologically compatible salts for the preparation of drugs for treatment of cancer is described. New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compositions. They can be identified by appropriate screens.
• [EN] THERAPEUTIC COMBINATIONS, LIQUID PHARMACEUTICAL COMPOSITIONS, KITS FOR THEIR PREPARATION, AND METHODS OF THEIR USE<br/>[FR] ASSOCIATIONS THÉRAPEUTIQUES, COMPOSITIONS PHARMACEUTIQUES LIQUIDES, KITS POUR LEUR PRÉPARATION ET LEURS MÉTHODES D'UTILISATION
  申请人：PREVEP LLC

  公开号：WO2020214960A1

  公开（公告）日：2020-10-22

  Disclosed are liquid pharmaceutical compositions including topiramate or a pharmaceutically acceptable salt thereof, meglumine, and a pharmaceutically acceptable excipient. The liquid pharmaceutical composition may further include, e.g., levetiracetam or brivaracetam and/or atorvastatin or a pharmaceutically acceptable salt thereof (e.g., atorvastatin sodium).